文献速递胸部肿瘤放疗放疗物理与技术

质子束治疗降低局部晚期非小细胞肺癌放化疗期间重度放射性淋巴细胞减少风险

Proton beam therapy reduces the risk of severe radiation-induced lymphopenia during chemoradiotherapy for locally advanced non-small cell lung cancer: A comparative analysis of proton versus photon therapy.
PubMed 文献 · Radiother Oncol · 2020-12-24

该回顾性研究纳入223例接受根治性同步放化疗的局部晚期非小细胞肺癌患者,其中29例接受笔束扫描质子治疗(PBSPT),194例接受调强光子放疗(IMRT)。结果显示PBSPT组重度放射性淋巴细胞减少(SRL)发生率显著低于IMRT组(OR 0.13,p=0.003),且肺V5Gy是SRL最强预测因子;中位随访23.0个月,伴SRL患者2年总生存劣于无SRL者(63.4% vs 79.9%,p=0.003)。

要点

  • PBSPT较IMRT显著降低SRL风险(OR 0.13,p=0.003)。
  • 肺V5Gy是SRL最强预测因子(OR 1.11,PSM后OR 1.07)。
  • 伴SRL患者2年总生存劣于无SRL者(63.4% vs 79.9%)。

核心结论

  • PBSPT通过减少肺部受照体积降低SRL,肺V5Gy参与SRL发生,优化放疗减少SRL可能对改善结局至关重要。

研究设计与样本

  • 回顾性比较分析,纳入223例接受根治性同步放化疗的局部晚期非小细胞肺癌患者,PBSPT组29例,IMRT组194例。

主要发现

  • PBSPT组与IMRT组基线绝对淋巴细胞计数(ALC)中位数分别为2130 vs 2040 cells/μL(p=0.983)。
  • PBSPT组肺接受≥5-20 GyE的体积及平均剂量显著低于IMRT组(p<0.001)。
  • 72例(32.3%)发生SRL,其中IMRT组69例(95.8%),PBSPT组3例(4.2%)。
  • 多因素分析显示PBSPT较IMRT降低SRL(OR 0.13,p=0.003)。
  • 中位随访23.0个月,伴SRL者2年总生存63.4%,无SRL者79.9%(p=0.003)。

关键数值与推荐

  • SRL定义为治疗期间每周实验室检查中至少2次绝对淋巴细胞计数(ALC)<200 cells/μL。
  • 采用逐步多因素逻辑回归(10折交叉验证)及1:2倾向性评分匹配(PSM)分析。
  • 肺V5Gy在PSM前OR 1.11、PSM后OR 1.07(p<0.05),为SRL最强预测因子。

临床怎么用

  • 对于局部晚期非小细胞肺癌同步放化疗患者,选择PBSPT可能降低SRL风险。
  • 计划设计时应关注肺V5Gy等低剂量受照体积,以降低SRL风险。

局限性

  • 回顾性研究设计,PBSPT组样本量较小(n=29),可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

HYPOTHESIS: We investigated differences in severe radiation-induced lymphopenia (SRL) after pencil beam scanning proton therapy (PBSPT) or intensity-modulated (photon) radiotherapy (IMRT) for patients with locally advanced non-small cell lung cancer. METHODS: We retrospectively reviewed 223 patients who received definitive concurrent chemoradiotherapy with PBSPT (n = 29) or IMRT (n = 194). SRL was defined when ≥2 events of absolute lymphocyte counts (ALCs) of <200 cells/μL were observed in weekly laboratory tests conducted during treatment. Stepwise multivariate logistic regression with 10-fold cross-validation was performed to identify predictive values of SRL. Furthermore, 1:2 propensity score matching (PSM) analysis was performed between the PBSPT and IMRT groups. RESULTS: Baseline ALC was comparable between the PBSPT and IMRT groups (median, 2130 vs. 2040 cells/μL; p = 0.983). Lung volumes receiving ≥ 5-20 GyE and the mean dose were significantly lower in patients receiving PBSPT than those receiving IMRT (p < 0.001). Among 72 (32.3%) patients with SRL; 69 (95.8%) and 3 (4.2%) patients were treated with IMRT and PBSPT, respectively. After multivariable analysis, PBSPT reduced SRL compared to IMRT (odds ratio [OR] 0.13, p = 0.003). Specifically, lung V5Gy were identified as the strongest predictor of SRL before (OR 1.11) and after PSM (OR, 1.07) (p < 0.05). With a median follow-up of 23.0 months, the 2-year overall survival in patients with SRL was worse than that those without SRL (63.4% vs. 79.9%; p = 0.003). CONCLUSIONS: Reduced irradiated lung volumes of PBSPT consequently reduced SRL. In addition, lung V5Gy contributed to the SRL. Reduction of SRL through the optimized RT might be essential to improve the outcomes.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Kim N, Myoung Noh J, Lee W, et al. Proton beam therapy reduces the risk of severe radiation-induced lymphopenia during chemoradiotherapy for locally advanced non-small cell lung cancer: A comparative analysis of proton versus photon therapy. Radiother Oncol. 2020. PMID: 33359267. doi:10.1016/j.radonc.2020.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。